National Institutes of Health (NIH)-Sponsored Consortium of Food Allergy Research (CoFAR) Starts a Phase 2 Clinical Study With DBV Technologies' Viaskin® Peanut in the Treatment of Peanut Allergy
10/24/2013 9:38:03 AM
NEW YORK, and BAGNEUX, France, Oct. 24, 2013 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new approach in the treatment of allergies, and the Consortium For Food Allergy Research (CoFAR) announced today that the CoFAR started enrolling patients into a multi-center, randomized, double-blinded, placebo-controlled trial using Viaskin® Peanut to treat children and adults with peanut allergy. The trial "Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase II study in Children and Adult" is also known as CoFAR6.
Help employers find you! Check out all the jobs and post your resume.
comments powered by